ducovest

SNY:NSD-Sanofi ADR (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 47.97

Change

0.00 (0.00)%

Market Cap

USD 134.67B

Volume

3.65M

Analyst Target

USD 56.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Company Website : https://www.sanofi.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

 USD 202.73B
AMGN Amgen Inc

N/A

 USD 152.45B
GILD Gilead Sciences Inc

N/A

 USD 111.44B
BIIB Biogen Inc

N/A

 USD 25.32B
GRFS Grifols SA ADR

N/A

 USD 6.92B
AMRN Amarin Corporation PLC

N/A

 USD 0.21B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

 USD 0.03B
SCLX Scilex Holding Company

N/A

 N/A
SCLXW Scilex Holding Company

N/A

 N/A

ETFs Containing SNY

PINK Simplify Exchange Traded .. 4.89 % 0.00 %

N/A

 USD 0.18B
HVAX:CA 4.85 % 0.00 %

N/A

 N/A
SEUC:SW SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

N/A

 USD 1.11B
ADRD 0.00 % 0.26 %

N/A

 N/A
ADRU 0.00 % 0.30 %

N/A

 N/A
EUR:CA 0.00 % 0.66 %

N/A

 N/A
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

 CAD 0.22B
HIG-U:CA 0.00 % 0.00 %

N/A

 N/A
SANE 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.54% 70% C- 43% F
Dividend Return 4.10% 100% F 69% C-
Total Return 0.56% 70% C- 46% F
Trailing 12 Months  
Capital Gain 2.02% 80% B- 44% F
Dividend Return 4.33% 100% F 61% D-
Total Return 6.35% 80% B- 48% F
Trailing 5 Years  
Capital Gain 3.79% 57% F 53% F
Dividend Return 20.86% 80% B- 78% C+
Total Return 24.65% 57% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 80% B- 42% F
Dividend Return 4.89% 80% B- 50% F
Total Return 3.70% 100% F 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 11.32% 100% F 87% B+
Risk Adjusted Return 43.21% 80% B- 73% C
Market Capitalization 134.67B 75% C 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector